sibutramine has been researched along with Disease Models, Animal in 16 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies have reported on the glucose and lipid-lowering effects of ferulic acid (FA) but its anti-obesity potential has not yet been firmly established." | 7.85 | Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesity. ( Carvalho, KM; da Cruz Fonseca, SG; de Lemos, TL; de Melo, TS; de Queiroz, MG; Fontenele, TM; Lima, PR; Rao, VS; Santos, FA; Solon, FR; Tomé, AR, 2017) |
| "To characterize the interactive effects of amylin with phentermine or sibutramine on food intake, body weight/composition and gene expression in diet-induced obese (DIO) rats." | 7.74 | Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. ( Athanacio, J; Coffey, T; Kesty, NC; Lei, C; Mack, C; Parkes, DG; Roth, JD; Trevaskis, JL; Weyer, C; Wilson, J, 2008) |
| "Sibutramine is an anorexiant drug that inhibits the reuptake of noradrenaline and serotonin, a pharmacological property shared with drugs clinically effective in treating anxiety pathologies." | 7.72 | Effects of sibutramine on anxiety-related behaviours in rats. ( de Oliveira, AM; de Paula Soares, V; Jorge, SD; Pobbe, RL; Zangrossi, H, 2004) |
| "Linagliptin treatment profoundly reduced hepatic fat compared with vehicle, with an effect comparable to that of sibutramine." | 5.38 | Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine. ( Cheetham, S; Ittrich, C; Kassubek, J; Klein, T; Mark, M; Mayoux, E; Mueller, HP; Niessen, HG; Stiller, D, 2012) |
| "Previous studies have reported on the glucose and lipid-lowering effects of ferulic acid (FA) but its anti-obesity potential has not yet been firmly established." | 3.85 | Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesity. ( Carvalho, KM; da Cruz Fonseca, SG; de Lemos, TL; de Melo, TS; de Queiroz, MG; Fontenele, TM; Lima, PR; Rao, VS; Santos, FA; Solon, FR; Tomé, AR, 2017) |
| "Sibutramine is widely used as a weight-loss substance in the treatment of obesity and is a selective inhibitor of the neuronal reuptake of serotonin and noradrenaline." | 3.79 | Rats on a high-energy diet showing no weight gain present with ultrastructural changes associated with liver fibrosis. ( Bester, MJ; Oberholzer, HM; van der Schoor, C, 2013) |
| "To characterize the interactive effects of amylin with phentermine or sibutramine on food intake, body weight/composition and gene expression in diet-induced obese (DIO) rats." | 3.74 | Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. ( Athanacio, J; Coffey, T; Kesty, NC; Lei, C; Mack, C; Parkes, DG; Roth, JD; Trevaskis, JL; Weyer, C; Wilson, J, 2008) |
| "The spironolactone Y5 antagonist significantly reduced body weight in C57BL DIO mice, but not in Npy5r(-/-) DIO mice." | 3.74 | Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. ( Fukami, T; Gomori, A; Ishihara, A; Ito, J; Iwaasa, H; Kanatani, A; Kitazawa, H; MacNeil, DJ; Mashiko, S; Matsushita, H; Mitobe, Y; Moriya, R; Takahashi, T; Van der Ploeg, LH, 2008) |
| "Sibutramine is an anorexiant drug that inhibits the reuptake of noradrenaline and serotonin, a pharmacological property shared with drugs clinically effective in treating anxiety pathologies." | 3.72 | Effects of sibutramine on anxiety-related behaviours in rats. ( de Oliveira, AM; de Paula Soares, V; Jorge, SD; Pobbe, RL; Zangrossi, H, 2004) |
| "Obesity is characterised by pathophysiological defects affecting both sides of the energy balance equation." | 2.40 | What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. ( Astrup, A; Lundsgaard, C, 1998) |
| "Linagliptin treatment profoundly reduced hepatic fat compared with vehicle, with an effect comparable to that of sibutramine." | 1.38 | Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine. ( Cheetham, S; Ittrich, C; Kassubek, J; Klein, T; Mark, M; Mayoux, E; Mueller, HP; Niessen, HG; Stiller, D, 2012) |
| "After 14 weeks of treatment, body weight, abdominal fat, blood lipid and serum insulin level were measured, and the protein and gene expression of PTP1B in liver tissue was tested." | 1.37 | Hepatic PTP1B expression involvement in the effects of Chinese medicine formula xiao-gao-jiang-zhuo using an obese rat model. ( Chang, B; Li, M; Liu, WK; Qin, PJ; Tong, XL; Zhen, Z, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Balavoine, F | 1 |
| Malabre, P | 1 |
| Alleaume, T | 1 |
| Rey, A | 1 |
| Cherfils, V | 1 |
| Jeanneton, O | 1 |
| Seigneurin-Venin, S | 1 |
| Revah, F | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Oberholzer, HM | 1 |
| Bester, MJ | 1 |
| van der Schoor, C | 1 |
| de Melo, TS | 1 |
| Lima, PR | 1 |
| Carvalho, KM | 1 |
| Fontenele, TM | 1 |
| Solon, FR | 1 |
| Tomé, AR | 1 |
| de Lemos, TL | 1 |
| da Cruz Fonseca, SG | 1 |
| Santos, FA | 1 |
| Rao, VS | 1 |
| de Queiroz, MG | 1 |
| Roth, JD | 1 |
| Trevaskis, JL | 1 |
| Wilson, J | 1 |
| Lei, C | 1 |
| Athanacio, J | 1 |
| Mack, C | 1 |
| Kesty, NC | 1 |
| Coffey, T | 1 |
| Weyer, C | 1 |
| Parkes, DG | 1 |
| Cifani, C | 1 |
| Polidori, C | 1 |
| Melotto, S | 1 |
| Ciccocioppo, R | 1 |
| Massi, M | 1 |
| Madsen, AN | 1 |
| Hansen, G | 1 |
| Paulsen, SJ | 1 |
| Lykkegaard, K | 1 |
| Tang-Christensen, M | 1 |
| Hansen, HS | 1 |
| Levin, BE | 1 |
| Larsen, PJ | 1 |
| Knudsen, LB | 1 |
| Fosgerau, K | 1 |
| Vrang, N | 1 |
| Frassetto, SS | 1 |
| Alves, IO | 1 |
| Santos, MM | 1 |
| Schmidt, AE | 1 |
| Lopes, JJ | 1 |
| Oliveira, PA | 1 |
| Vinagre, AS | 1 |
| Pereira, P | 1 |
| Li, M | 1 |
| Chang, B | 1 |
| Zhen, Z | 1 |
| Qin, PJ | 1 |
| Liu, WK | 1 |
| Tong, XL | 1 |
| Klein, T | 1 |
| Niessen, HG | 1 |
| Ittrich, C | 1 |
| Mayoux, E | 1 |
| Mueller, HP | 1 |
| Cheetham, S | 1 |
| Stiller, D | 1 |
| Kassubek, J | 1 |
| Mark, M | 1 |
| Matsumoto, K | 1 |
| Iijima, H | 1 |
| Jorge, SD | 1 |
| Pobbe, RL | 1 |
| de Paula Soares, V | 1 |
| de Oliveira, AM | 1 |
| Zangrossi, H | 1 |
| Xu, J | 1 |
| Dz Chen, J | 1 |
| Mashiko, S | 1 |
| Ishihara, A | 1 |
| Iwaasa, H | 1 |
| Moriya, R | 1 |
| Kitazawa, H | 1 |
| Mitobe, Y | 1 |
| Ito, J | 1 |
| Gomori, A | 1 |
| Matsushita, H | 1 |
| Takahashi, T | 1 |
| MacNeil, DJ | 1 |
| Van der Ploeg, LH | 1 |
| Fukami, T | 1 |
| Kanatani, A | 1 |
| Astrup, A | 1 |
| Lundsgaard, C | 1 |
| Bickerdike, MJ | 1 |
| Vickers, SP | 1 |
| Dourish, CT | 1 |
2 reviews available for sibutramine and Disease Models, Animal
| Article | Year |
|---|---|
What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
Topics: Adrenergic beta-Agonists; Animals; Appetite Depressants; Caffeine; Central Nervous System Stimulants | 1998 |
5-HT2C receptor modulation and the treatment of obesity.
Topics: Animals; Appetite Depressants; Cyclobutanes; Disease Models, Animal; Fenfluramine; Humans; Obesity; | 1999 |
14 other studies available for sibutramine and Disease Models, Animal
| Article | Year |
|---|---|
Design and synthesis of novel hydantoin-containing melanin-concentrating hormone receptor antagonists.
Topics: Animals; Chemistry, Pharmaceutical; Depression; Disease Models, Animal; Drug Design; Feeding Behavio | 2007 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Rats on a high-energy diet showing no weight gain present with ultrastructural changes associated with liver fibrosis.
Topics: Animals; Appetite Depressants; Body Mass Index; Cyclobutanes; Diet, High-Fat; Disease Models, Animal | 2013 |
Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesity.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Coumaric Acids; Cyclobutanes; Diet, High-Fat; Disease | 2017 |
Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
Topics: Amyloid; Animals; Anti-Obesity Agents; Body Composition; Body Weight; Cyclobutanes; Diet; Disease Mo | 2008 |
A preclinical model of binge eating elicited by yo-yo dieting and stressful exposure to food: effect of sibutramine, fluoxetine, topiramate, and midazolam.
Topics: Animals; Appetite Depressants; Behavior, Animal; Bulimia; Cyclobutanes; Disease Models, Animal; Eati | 2009 |
Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome.
Topics: Analysis of Variance; Animals; Appetite Depressants; Blood Glucose; Cyclobutanes; Diet; Disease Mode | 2010 |
Absence of sibutramine effect on spontaneous anxiety in rats.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anti-Obesity Agents; Anxiety; Body Weight; Cyclo | 2010 |
Hepatic PTP1B expression involvement in the effects of Chinese medicine formula xiao-gao-jiang-zhuo using an obese rat model.
Topics: Abdominal Fat; Animals; Anti-Obesity Agents; Body Weight; Cholesterol; Cyclobutanes; Dietary Fats; D | 2011 |
Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine.
Topics: Adiposity; Animals; Appetite Depressants; Body Composition; Cyclobutanes; Disease Models, Animal; Fe | 2012 |
Sibutramine sensitivity assay revealed a unique phenotype of bombesin BB3 receptor-deficient mice.
Topics: Animals; Appetite Depressants; Cyclobutanes; Disease Models, Animal; Feeding Behavior; Female; Hyper | 2003 |
Effects of sibutramine on anxiety-related behaviours in rats.
Topics: Animals; Anxiety; Cyclobutanes; Darkness; Disease Models, Animal; Dose-Response Relationship, Drug; | 2004 |
Effects of sibutramine on gastric emptying, intestinal motility and rectal tone in dogs.
Topics: Administration, Oral; Animals; Appetite Depressants; Compliance; Cyclobutanes; Disease Models, Anima | 2008 |
Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
Topics: Adiposity; Animals; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Weight; Caloric R | 2008 |